Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Breakthrough in koala chlamydia treatment
koalas
As specialised eucalyptus herbivores, koalas are notoriously poor to respond to antibiotic therapy because of their unique metabolism.
Scientists identify ‘highly successful’ compound

Microbiologist Dr Willa Huston from the University of Technology Sydney has identified a chemical that could lead to a new antibiotic treatment for chlamydia in koalas.  

Extensive testing of tissue samples has unveiled a chemical compound that is low in toxicity yet highly successful in killing the bacteria. With chlamydial disease affecting as many as nine in 10 koalas in some areas, populations are now listed as ‘vulnerable’ in NSW and Queensland.

Currently, specialist koala vets use Baytril and Chloramphenicol 150 to treat the disease. However, with supplies of Chloramphenicol 150 being removed from the market, and variable success rates with current therapies, the new compound could be a crucial breakthrough.

Dr Willa Huston said: “It’s really urgent that we put a concerted effort into developing this treatment further.”

Koalas are affected by two strains of chlamydia, C. pecorum causing eye disease or urogenital disease and infertility, and C. pneumonia causing severe respiratory illness. As specialised eucalyptus herbivores, koalas are notoriously poor to respond to antibiotic therapy because of their unique metabolism.

“We are in a desperate search to find new, effective treatments and test other drugs that might help koalas recover from this horrible disease”.

Dr Huston and her team are now refining the chemical make up before advancing to testing on diseased koalas.

“Time is running out. We all treasure our koalas and we need to do everything we can to cure this disease.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.